organization · Reporting owner
Sumitovant Biopharma Ltd.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Urovant Sciences Ltd.UROV · Entity 140739 | 10% owner | February 19, 2020 | February 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Urovant Sciences Ltd.
Report date February 19, 2020 · Filed February 21, 2020
Jointly reported with Sumitomo Chemical Co., Ltd., Sumitomo Pharma Co., Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 22,963,263 |
Last balance in matching sequence
After 2020-02-19 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-02-19 · Purchase · Acquired 12,873 · Balance 22,872,886 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Row 2 · 2020-02-19 · Purchase · Acquired 15,165 · Balance 22,888,051 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Row 3 · 2020-02-19 · Purchase · Acquired 75,212 · Balance 22,963,263 F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Jointly reported with Sumitomo Chemical Co., Ltd., Sumitomo Pharma Co., Ltd.
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 45,798,176 |
Reported balance
After 2023-03-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-03-10 · Purchase · Acquired 51,599,200 · Balance 45,798,176 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. F2: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes. F3: Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of Myovant Sciences Ltd. (the "Issuer") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto.
F2: (Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes.
F3: Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2020 Filed May 13, 2020 22:50 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 24,448 | $13.51 | $330,404.94 |
DisclosureSEC source: 0000899243-20-013027 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,377,141 F4 · shares: This acquisition of a total of 24,448 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,377,141 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:50 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 35,000 | $12.78 | $447,384.00 |
DisclosureSEC source: 0000899243-20-013027 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,352,693 F1 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,352,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:01 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 35,000 | $12.83 | $449,074.50 |
DisclosureSEC source: 0000899243-20-012570 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,317,693 F4 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,317,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:01 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 35,000 | $12.63 | $442,137.50 |
DisclosureSEC source: 0000899243-20-012570 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,282,693 F1 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,282,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 06, 2020 Filed May 11, 2020 20:07 UTC Amendment | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $12.24 | $612,075.00 |
DisclosureSEC source: 0000899243-20-012574 · doc4a.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,247,693 F1 · date: On May 7, 2020, the Reporting Persons filed a Form 4 disclosing the acquisition of 50,000 shares of Common Stock at an average stock price of $11.6893 (the "First Acquisition") and 50,000 shares of Common Stock at an average stock price of $12.2415 (the "Second Acquisition"). The transaction date reported in Box 2 for both the First Acquisition and the Second Acquisition was May 5, 2020. The transaction date for the Second Acquisition was incorrectly reported and should have been reported as May 6, 2020. F2 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F3 · price: The price reported in column 4 is the average stock price. F4 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 05, 2020 Filed May 7, 2020 13:26 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $12.24 | $612,075.00 |
DisclosureSEC source: 0000899243-20-012209 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,247,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 05, 2020 Filed May 7, 2020 13:26 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $11.69 | $584,465.00 |
DisclosureSEC source: 0000899243-20-012209 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,197,693 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,197,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 04, 2020 Filed May 5, 2020 19:40 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $11.50 | $574,870.00 |
DisclosureSEC source: 0000899243-20-012040 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,147,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,147,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 01, 2020 Filed May 5, 2020 19:40 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $11.38 | $569,180.00 |
DisclosureSEC source: 0000899243-20-012040 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,097,693 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,097,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:35 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $12.08 | $603,825.00 |
DisclosureSEC source: 0000899243-20-011728 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 48,047,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 48,047,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 29, 2020 Filed May 1, 2020 21:35 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $11.92 | $595,895.00 |
DisclosureSEC source: 0000899243-20-011728 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,997,693 F1 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,997,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 28, 2020 Filed Apr 29, 2020 17:38 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $12.05 | $602,720.00 |
DisclosureSEC source: 0000899243-20-011506 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,947,693 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,947,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 17:38 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 40,503 | $12.18 | $493,302.24 |
DisclosureSEC source: 0000899243-20-011506 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,897,693 F1 · shares: This acquisition of a total of 40,503 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,897,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 15:30 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 43,086 | $12.15 | $523,344.10 |
DisclosureSEC source: 0000899243-20-011334 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,857,190 F4 · shares: This acquisition of a total of 43,086 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,857,190 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 15:30 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 35,000 | $12.35 | $432,103.00 |
DisclosureSEC source: 0000899243-20-011334 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,814,104 F1 · shares: This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,814,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 18:21 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,000 | $11.93 | $596,730.00 |
DisclosureSEC source: 0000899243-20-011209 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,779,104 F4 · shares: This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,779,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 18:21 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,200 | $11.58 | $581,140.30 |
DisclosureSEC source: 0000899243-20-011209 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,729,104 F1 · shares: This acquisition of a total of 50,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,729,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 20:01 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 50,300 | $11.82 | $594,425.28 |
DisclosureSEC source: 0000899243-20-011041 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,678,904 F4 · shares: This acquisition of a total of 50,300 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,678,904 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 20:01 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $10.76 | $753,536.00 |
DisclosureSEC source: 0000899243-20-011041 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,628,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,628,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 16, 2020 Filed Apr 17, 2020 16:38 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $10.64 | $744,674.00 |
DisclosureSEC source: 0000899243-20-010899 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,558,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,558,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:38 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $10.48 | $733,698.00 |
DisclosureSEC source: 0000899243-20-010899 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,488,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,488,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 23:22 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $11.00 | $770,105.00 |
DisclosureSEC source: 0000899243-20-010804 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,418,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,418,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 23:22 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $9.81 | $686,546.00 |
DisclosureSEC source: 0000899243-20-010804 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,348,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,348,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 18:25 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $9.37 | $655,669.00 |
DisclosureSEC source: 0000899243-20-010666 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,278,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,278,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 15:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $8.53 | $596,939.00 |
DisclosureSEC source: 0000899243-20-010563 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,208,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,208,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 15:20 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $8.21 | $574,364.00 |
DisclosureSEC source: 0000899243-20-010563 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,138,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 47,138,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 17:56 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $8.44 | $590,520.00 |
DisclosureSEC source: 0000899243-20-010382 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 47,068,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 47,068,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:56 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $7.93 | $554,925.00 |
DisclosureSEC source: 0000899243-20-010382 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,998,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,998,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 19:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $7.73 | $541,086.00 |
DisclosureSEC source: 0000899243-20-010095 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,928,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,928,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 19:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $7.46 | $522,298.00 |
DisclosureSEC source: 0000899243-20-010095 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,858,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,858,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 14:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $7.97 | $557,984.00 |
DisclosureSEC source: 0000899243-20-009776 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,788,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,788,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 14:55 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $7.65 | $535,766.00 |
DisclosureSEC source: 0000899243-20-009776 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,718,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,718,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 15:34 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $7.98 | $558,250.00 |
DisclosureSEC source: 0000899243-20-009633 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,648,604 F4 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,648,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 15:34 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 70,000 | $7.94 | $555,807.00 |
DisclosureSEC source: 0000899243-20-009633 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,578,604 F1 · shares: This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,578,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 15:39 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 108,100 | $7.60 | $821,895.11 |
DisclosureSEC source: 0000899243-20-009469 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,508,604 F4 · shares: This acquisition of a total of 108,100 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,508,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 15:39 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 211,200 | $7.67 | $1,620,558.72 |
DisclosureSEC source: 0000899243-20-009469 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,400,504 F1 · shares: This acquisition of a total of 211,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,400,504 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 19:15 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 211,200 | $7.68 | $1,621,931.52 |
DisclosureSEC source: 0000899243-20-009332 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,189,304 F4 · shares: This acquisition of a total of 211,200 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. F2 · price: The price reported in column 4 is the average stock price. F5 · ownership.nature: Sumitovant directly owns 46,189,304 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 19:15 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 193,900 | $7.60 | $1,472,709.28 |
DisclosureSEC source: 0000899243-20-009332 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,978,104 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 45,978,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 18:10 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 193,900 | $7.68 | $1,488,958.10 |
DisclosureSEC source: 0000899243-20-009088 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,784,204 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F4 · ownership.nature: Sumitovant directly owns 45,784,204 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 18:10 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 193,900 | $7.40 | $1,434,937.56 |
DisclosureSEC source: 0000899243-20-009088 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,590,304 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 45,590,304 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 20:21 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 193,900 | $7.40 | $1,433,948.67 |
DisclosureSEC source: 0000899243-20-008835 · doc4.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,396,404 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F4 · ownership.nature: Sumitovant directly owns 45,396,404 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:21 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | PurchaseCommon Stock | 193,900 | $7.25 | $1,406,007.68 |
DisclosureSEC source: 0000899243-20-008835 · doc4.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · 10% owner Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · 10% owner Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,202,504 F1 · shares: This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. F2 · price: The price reported in column 4 is the average stock price. F3 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 45,202,504 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:54 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Stock | 75,212 | $13.08 | $983,772.96 |
DisclosureSEC source: 0000950103-20-003118 · dp121731_4-sumitomo.xml · nonDerivative · entry 3 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · See Footnote (1) Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · See Footnote (1) Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,963,263 F1 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:54 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Stock | 15,165 | $13.08 | $198,358.20 |
DisclosureSEC source: 0000950103-20-003118 · dp121731_4-sumitomo.xml · nonDerivative · entry 2 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · See Footnote (1) Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · See Footnote (1) Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,888,051 F1 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:54 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Stock | 12,873 | $13.08 | $168,378.84 |
DisclosureSEC source: 0000950103-20-003118 · dp121731_4-sumitomo.xml · nonDerivative · entry 1 Sumitomo Chemical Co., Ltd. · CIK 0001798550 · See Footnote (1) Dainippon Sumitomo Pharma Co Ltd · CIK 0001446601 · See Footnote (1) Sumitovant Biopharma Ltd. · CIK 0001798244 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,872,886 F1 · ownership.nature: Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.